Ricardo Osorio

Array ( [id] => 15753761 [patent_doc_number] => 10618976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => SIRP-a agonist antibody [patent_app_type] => utility [patent_app_number] => 15/577565 [patent_app_country] => US [patent_app_date] => 2016-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 13644 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13636777 [patent_doc_number] => 09845345 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-19 [patent_title] => SIRP polypeptide compositions and methods of use [patent_app_type] => utility [patent_app_number] => 15/157291 [patent_app_country] => US [patent_app_date] => 2016-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 20487 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15157291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11434861 [patent_doc_number] => 20170035883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'Methods and Compositions for Treating Conditions of the Eye' [patent_app_type] => utility [patent_app_number] => 15/155495 [patent_app_country] => US [patent_app_date] => 2016-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11329 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15155495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605990 [patent_doc_number] => 10906982 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Antagonistic anti-tumor necrosis factor receptor 2 antibodies [patent_app_type] => utility [patent_app_number] => 15/573747 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 67 [patent_no_of_words] => 59230 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15573747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15606249 [patent_doc_number] => 10584174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-10 [patent_title] => Anti-Dkk-1-anti-RANKL bispecific antibody compounds [patent_app_type] => utility [patent_app_number] => 15/570756 [patent_app_country] => US [patent_app_date] => 2016-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10694 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15570756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16640918 [patent_doc_number] => 10918739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => sDR5-Fc fusion protein mutant and use thereof [patent_app_type] => utility [patent_app_number] => 15/738210 [patent_app_country] => US [patent_app_date] => 2016-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 5568 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15738210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12302433 [patent_doc_number] => 09937165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => Pharmacological chaperones for treating obesity [patent_app_type] => utility [patent_app_number] => 15/148693 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 18880 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12220761 [patent_doc_number] => 20180059122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'NOVEL MARKER FOR GESTATIONAL DIABETES' [patent_app_type] => utility [patent_app_number] => 15/559299 [patent_app_country] => US [patent_app_date] => 2016-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8434 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16832144 [patent_doc_number] => 11008385 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Agents for use in the therapeutic treatment of hyperopia [patent_app_type] => utility [patent_app_number] => 15/558139 [patent_app_country] => US [patent_app_date] => 2016-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10752 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12204863 [patent_doc_number] => 20180050090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'COMPOSITIONS AND METHODS FOR SENSITIZING CELLS TO TRAIL-INDUCED APOPTOSIS' [patent_app_type] => utility [patent_app_number] => 15/559108 [patent_app_country] => US [patent_app_date] => 2016-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 11946 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15193863 [patent_doc_number] => 10494410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Inhibitor Peptides of ERK-type MAP kinase [patent_app_type] => utility [patent_app_number] => 15/049825 [patent_app_country] => US [patent_app_date] => 2016-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 6785 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15049825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806570 [patent_doc_number] => 20160152728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII' [patent_app_type] => utility [patent_app_number] => 15/015261 [patent_app_country] => US [patent_app_date] => 2016-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 17978 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15015261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806564 [patent_doc_number] => 20160152722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/012414 [patent_app_country] => US [patent_app_date] => 2016-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 21481 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15012414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440577 [patent_doc_number] => 20180271831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => NEW COMPOSITIONS AND METHODS OF TREATING AND/OR PREVENTING CHRONIC OBSTRUCTIVE PULMONARY DISEASE [patent_app_type] => utility [patent_app_number] => 15/547099 [patent_app_country] => US [patent_app_date] => 2016-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15547099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118844 [patent_doc_number] => 20180002431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'FAS AND DRs ARE NOVEL MOLECULAR TARGETS OF SENESCENT CELLS' [patent_app_type] => utility [patent_app_number] => 15/545479 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 16849 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15545479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16320170 [patent_doc_number] => 10780117 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Macrophages eat cancer cells using their own calreticulin as a guide [patent_app_type] => utility [patent_app_number] => 15/543095 [patent_app_country] => US [patent_app_date] => 2016-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 42 [patent_no_of_words] => 15121 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15543095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16640896 [patent_doc_number] => 10918717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Pharmaceutical formulation comprising anti-EGFR antibody [patent_app_type] => utility [patent_app_number] => 15/544335 [patent_app_country] => US [patent_app_date] => 2016-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 33 [patent_no_of_words] => 5789 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12138263 [patent_doc_number] => 20180016346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'BISPECIFIC ANTIBODY BINDING TO TRAILR2 AND PSMA' [patent_app_type] => utility [patent_app_number] => 15/541872 [patent_app_country] => US [patent_app_date] => 2016-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 46660 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15541872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13251219 [patent_doc_number] => 10138289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => Method for producing antibody using "naked" expression vector expressing type II transmembrane fusion protein [patent_app_type] => utility [patent_app_number] => 14/988595 [patent_app_country] => US [patent_app_date] => 2016-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 17 [patent_no_of_words] => 19149 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14988595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717267 [patent_doc_number] => 20170369588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => PRO-APOPTOTIC ANTI-NG2/CSPG4 ANTIBODIES AND THEIR USES FOR DISEASE THERAPY [patent_app_type] => utility [patent_app_number] => 15/538659 [patent_app_country] => US [patent_app_date] => 2015-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15538659 [rel_patent_id] =>[rel_patent_doc_number] =>)